Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation
Shots:
- Abbott has received European CE Mark for its Volt PFA System to treat pts with atrial fibrillation; commercialization has begun, with further expansion in EU markets expected by H2’25
- Approval was based on CE Mark study in the EU & Australia, showing that the Volt achieved pulmonary vein isolation (PVI) in 99.1% veins with fewer energy applications than other marketed PFA systems
- Volt, integrated with Abbott’s EnSite X EP system, provides simplified workflow, efficient energy delivery via its balloon-in-basket design, plus procedural flexibility with sedation options & is being evaluated in the VOLT-AF IDE study, which completed early enrollment (n~400), with 12mos. follow-up expected in 2025
Ref: Prnewswire | Image: Abbott
Related News:- Abbott Reports First-in-Human Leadless Pacing Procedures Using AVEIR Conduction System Pacing (CSP) Leadless Pacemaker
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
